GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (BSP:H1ZN34) » Definitions » Price-to-Owner-Earnings

Horizon Therapeutics (BSP:H1ZN34) Price-to-Owner-Earnings : 39.62 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Horizon Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-11), Horizon Therapeutics's share price is R$58.24. Horizon Therapeutics's Owner Earnings per Share (TTM) ended in Jun. 2023 was R$1.47. It's Price-to-Owner-Earnings for today is 39.62.


The historical rank and industry rank for Horizon Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

BSP:H1ZN34' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.67   Med: 35.33   Max: 583.43
Current: 39.69

During the past 13 years, the highest Price-to-Owner-Earnings of Horizon Therapeutics was 583.43. The lowest was 13.67. And the median was 35.33.


BSP:H1ZN34's Price-to-Owner-Earnings is not ranked
in the Drug Manufacturers industry.
Industry Median: 27.85 vs BSP:H1ZN34: 39.69

As of today (2024-05-11), Horizon Therapeutics's share price is R$58.24. Horizon Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was R$0.58. Therefore, Horizon Therapeutics's PE Ratio (TTM) for today is 100.94.

As of today (2024-05-11), Horizon Therapeutics's share price is R$58.24. Horizon Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was R$0.58. Therefore, Horizon Therapeutics's PE Ratio without NRI for today is 100.94.

During the past 13 years, Horizon Therapeutics's highest PE Ratio without NRI was 208.89. The lowest was 9.23. And the median was 48.89.


Horizon Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Horizon Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Price-to-Owner-Earnings Chart

Horizon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 71.49 38.92 30.90

Horizon Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.15 14.80 30.90 - -

Competitive Comparison of Horizon Therapeutics's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Price-to-Owner-Earnings falls into.



Horizon Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Horizon Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=58.24/1.47
=39.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics  (BSP:H1ZN34) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Horizon Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (BSP:H1ZN34) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Horizon Therapeutics (BSP:H1ZN34) Headlines

No Headlines